Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,498
Recruiting: 782
Ph III recruiting: 85
Growth YoY: +17.8%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 51–100 of 1,752 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03460977	A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma	recruiting	Phase 1	453	PfizerINDUSTRY	8	Sep 25, 2026	clinicaltrials
NCT03564340	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	recruiting	Phase 1 / Phase 2	890	Regeneron PharmaceuticalsINDUSTRY	10	Sep 25, 2026